Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness (ANOWSM)

7 augustus 2026 bijgewerkt door: Shachi Tyagi, University of Pittsburgh

The goal of this clinical trial is to examine and compare the effect of behavioral sleep treatment: BBTI (brief behavioral treatment of insomnia) and brief mindfulness (MI), independently and combined vs control on frequency of nighttime awakenings to void (nocturia) and on nighttime urine production in older women over the age 65 years with nocturia.

To study the effect of these treatments, participants will be randomly assigned to one of the following groups 1) BBTI alone, 2) MI alone, 3) BBTI+MI, or 4) control: sleep information only without any structured sleep or mindfulness therapy.

The study aims to examine the effect of these therapies at end-of-treatment (week 4), as well sustained effects at 3- and 6-months. The main questions the study aims to answer are:

  1. do these treatments reduce the frequency of nighttime awakenings to void
  2. do these treatments reduce the volume of nighttime urine production
  3. do these treatments improve sleep quality

Frequency of nocturia and sleep quality will be assessed via questionnaires and nighttime urine volume using bladder-sleep diaries which is 3-day record participants will complete at home documenting every time they go to the bathroom and volume they voided. In addition, sleep and sleep interruptions will also be assessed using an FDA-cleared home sleep testing device called Zmachine®.

Studie Overzicht

Gedetailleerde beschrijving

Nocturia, or waking at night to void, and poor sleep are prevalent and comorbid conditions in the elderly. Nocturia affects up to 70% of those over age 60, and over 75% of the older adults with poor sleep report nocturia as the main reason. Nocturia increases risk for falls, fractures, depression, institutionalization, and death. Poor sleep and nocturia have a bidirectional relationship and are mutually exacerbating. Nocturnal polyuria (NP) or excess urine production during sleep is the major contributor to nocturia in the elderly and poor sleep is known to cause NP. Vasopressin and aldosterone peak during sleep, causing sodium and water reabsorption in renal tubuli, which leads to decrease in nighttime urine production. Sleep loss leads to attenuation of the sleep time release of these hormones, resulting in natriuresis and diuresis causing NP.

Brief behavioral treatment of insomnia (BBTI- a brief 4-week, efficacious behavioral treatment for insomnia) is effective in addressing sleep and nocturia. Investigators found in their recently concluded pilot trial among older adults with comorbid nocturia (≥2/night) and poor sleep, that BBTI improved nocturia more than control (-0.9 vs -0.3, p=.016). Compared to control, BBTI improved subjective insomnia severity index (-5.9 vs -2.5, p=.02). Additionally, BBTI also improved NP: % of 24h urine volume excreted at night decreased in BBTI vs control (-7.1±13%, p=.001 vs -4±11, p=.08). Although BBTI is brief and effective for nocturia, adherence to behavioral sleep treatments among patients with chronic conditions (poor sleep, nocturia) is disappointingly low compared to patients with acute conditions, particularly several months after therapy. Moreover, the time and personnel needed to train professionals and to administer the intervention has limited the scalability of this otherwise promising treatment. Alternatives to boost treatment adherence and maintain benefit need to be investigated.

Recently the investigators trialed brief mindfulness (MI) training alone or paired with transcranial direct current stimulation (tDCS) in older women with urinary incontinence to enhance cognitive control over bladder symptoms. Of these women, those who had nocturia (≥1/night) and received MI training alone experienced improvement in nocturia (-0.5±0.6, p=0.005) with a concurrent increase in FUSP (39.8±70.2 minutes, p=0.02). Interestingly, effect of MI on nocturia and FUSP were similar to that seen with BBTI. MI requires only brief training followed by convenient at-home use. It was well liked in our study with an acceptability of 85.6 and compliance of 94.4 on a 1-100 Likert scale indicating MI may be a simpler and scalable modality either alone or to augment BBTI for reducing nocturia in older women.

This study a randomized pilot trial in older women with interrupted sleep due to nocturia to examine the effect of BBTI and MI on nocturia, nighttime urine production, and sleep quality at 4-week (post-intervention) and 3- and 6-months later. The investigators postulate that both interventions, individually and in combination, will be beneficial, and the combined treatment will lead to sustained treatment effects at 3- and 6-months.

The study will include older women with nocturia. Sleep will be assessed subjectively with the Pittsburgh Sleep Quality Index (PSQI) and objectively using Zmachine®, an FDA cleared in-home single channel EEG device, and a 3-day bladder-sleep diary that concurrently assesses sleep and voiding pattern including frequency and volume during day and night. Participants will be randomized to one of the 4 groups in a 2x2 factorial design: i) BBTI, ii) MI, iii) BBTI+MI or iv) control. Participants will repeat the study measures at 4 weeks, and 3- and 6-months.

The study aims to explore the effects of MI and BBTI. Hypothesis: Compared to control, BBTI and/or MI groups will result in greater improvement in 1) nocturia, 2) volume of nighttime urine volume, and 3) sleep quality at 4 weeks with the combined BBTI+MI intervention conferring greater benefits and sustained treatment effects at 3- and 6-months.

This study will be the first RCT to evaluate the effect of BBTI and MI, individually and combined on nocturia and sleep, and to assess durability of benefit. The results will provide novel information regarding the promise of efficient cost-effective, and easy to disseminate means of treating nocturia in older women and facilitate confirmatory trial to provide definitive evidence and develop clinically acceptable treatment protocols.

Studietype

Ingrijpend

Inschrijving (Geschat)

80

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Shachi Tyagi, MD, MS
  • Telefoonnummer: 14126471274
  • E-mail: sht55@pitt.edu

Studie Contact Back-up

  • Naam: Becky D Clarkson, PhD
  • Telefoonnummer: 4126471270
  • E-mail: bdc29@pitt.edu

Studie Locaties

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15213
        • University of Pittsburgh
        • Contact:
          • Shachi Tyagi, MD, MS
          • Telefoonnummer: 412-647-1274
          • E-mail: sht55@pitt.edu
        • Contact:
          • Becky D Clarkson, PhD
          • Telefoonnummer: 412.647.1270
          • E-mail: bdc29@pitt.edu

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Female
  • Age > or =65 years
  • Nocturia ≥2/night
  • Poor sleep (Insomnia Severity Index ≥8)
  • MoCA (including trail making) >26

Exclusion Criteria:

  • Conditions that affect bladder function: Multiple sclerosis, Alzheimer's disease, spinal cord injury, urethral obstruction, urinary retention, interstitial cystitis, bladder cancer, radiation to the pelvic area, bladder surgery, current or uncontrolled chronic or recurrent bowel issues, bacterial endocarditis
  • cardiac or respiratory disease that limits daily function
  • Unstable or acute medical condition:

    - Any acute medical condition that requires immediate treatment such that it would interfere with the study protocol; Each instance will be assessed on a case-by-case basis by our study physician who may postpone a participant's enrollment; stably managed chronic conditions are exempt from this exclusion.

  • Untreated, current, severe psychiatric condition (assessed during Visit 1a- medical history)
  • Post void residual ≥ 200ml- assessed during baseline visit
  • Currently diagnosed and/or untreated obstructive sleep apnea, untreated restless leg syndrome, untreated parasomnia
  • Untreated or poorly controlled fluid overload conditions like CHF, diabetes

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Ander: Controle
The control condition is intended to emulate the behavioral treatment information generally available to patients.
Experimenteel: BBTI
Brief behavioral treatment of insomnia

BBTI: will entail a 45- to 60-minute individual intervention session with instructions regarding sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. This education provides the rationale for the 4 main interventions of BBTI:

  1. reduce time in bed;
  2. get up at the same time every day, regardless of sleep duration;
  3. do not go to bed unless sleepy; and
  4. do not stay in bed unless asleep
Experimenteel: MI
Brief mindfulness
Participants in the MI group will be trained to engage in a brief mindfulness method involving body scan with acceptance language training.
Experimenteel: BBTI+MI
Brief behavioral treatment of insomnia and brief mindfulness
Participants in this arm will receive BBTI as well as MI training.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Nocturia
Tijdsspanne: 4 weeks, 3- and 6-months post-intervention
number of nighttime awakenings to void
4 weeks, 3- and 6-months post-intervention

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Nocturnal polyuria index (NPi)
Tijdsspanne: 4 weeks, 3- and 6-months post-intervention
percentage of 24-hour urine volume excreted at night
4 weeks, 3- and 6-months post-intervention
Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: 4-weeks, 3- and 6-month post intervention
Self-reported sleep quality questionnaire scored by grouping 19 self-rated questions into seven component scores, summing them into a global score (0 to 21)> PSQI score >5 Indicates significant, poor sleep quality and clinical sleep disturbance.
4-weeks, 3- and 6-month post intervention

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Shachi Tyagi, MD, MS, University of Pittsburgh
  • Studie stoel: Shachi Tyagi, MD, MS, University of Pittsburgh
  • Studie directeur: Becky D Clarkson, PhD, University of Pittsburgh

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

15 september 2026

Primaire voltooiing (Geschat)

30 oktober 2028

Studie voltooiing (Geschat)

30 april 2029

Studieregistratiedata

Eerst ingediend

7 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

7 augustus 2026

Eerst geplaatst (Werkelijk)

12 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

7 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

All of the individual participant data collected during the trial, after deidentification may be shared with other researchers.

IPD-tijdsbestek voor delen

Following publication, no end date

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren